Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chantix effective

This article was originally published in The Tan Sheet

Executive Summary

Continuous smoking cessation rates for four weeks were significantly higher for patients taking varenicline tartrate (Pfizer's Chantix) 1 mg twice daily compared to placebo (48% versus 17.1%), according to a study published in the Archives of Internal Medicine August 14/28. The Pfizer-sponsored, randomized study included 638 smokers between ages 18 to 65 at seven U.S. sites, Mitchell Nides, PhD, et al., say. The researchers compared three dosages of varenicline, bupropion hydrochloride (GlaxoSmithKline's Zyban) and placebo for seven weeks with follow up through week 52. Efficacy was determined by exhaled carbon monoxide tests at weeks 12, 24, and 52, and daily dairies recording the number of cigarettes smoked. Chantix, 1 mg twice daily, "effectively helped subjects quit smoking, with response rates three times higher than those for placebo....Efficacy was maintained in the non-drug treatment phase through week 52," Nides et al. say. FDA approved prescription Chantix in May 1("The Tan Sheet" May 15, 2006, In Brief)...

You may also be interested in...

Rx smoking cessation pill

FDA has approved Pfizer's smoking cessation drug Chantix (varenicline) for prescription use, the agency announces May 11. The drug, which Pfizer originally had intended to market as Champix, is the first nicotine agonist approved by FDA, and the first new Rx medication approved for smoking cessation in more than a decade, according to the firm. Varenicline works by binding to nicotine receptors in the brain, thereby "providing some nicotine effects to ease withdrawal symptoms and...blocking the effects of nicotine from cigarettes if [people] resume smoking," FDA states. Pfizer expects Chantix to launch in the second half of 2006. The firm has stated in the past that it will draw from its Nicorette experience when developing DTC ads for Chantix (1"The Tan Sheet" Feb. 9, 2004, p. 5)...

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts